https://www.selleckchem.com/pr....oducts/anlotinib-al3
allopurinol, the frequency of alanine transaminase or aspartate transaminase 3× upper limit of normal in the pooled study populations was 3.6% for the tolvaptan+statin group and 2.3% for the placebo+statin group (difference 1.4%; -2.0% to 4.7%). CONCLUSIONS Tolvaptan has been used safely in combination with statins in clinical trials. PODCAST This article contains a podcast at https//www.asn-online.org/media/podca....st/CJASN/2020_04_06_ Copyright © 2020 by the American Society of Nephrology.It is estimated tha
Like
Comment
Share
